3.3. Clinical Response
DISEASE, REMISSION, METASTATIC DISEASE, RECURRENT DISEASE
The study obtained a 3.1% of complete remission and 15.4% of partial remission, which contributed to an objective response rate of 18.5%, and the disease control rate was achieved in 43.1% of the study patients (In patients who received 8 or more doses of nimotuzumab, the objective response increased to 26.1% and the disease control to 60.9%. In the stratum of patients with locally advanced disease, a 39.1% of objective response was obtained, and disease control was achieved in 60.9% of the patients. Those patients who received 8 or more doses of nimotuzumab reached a 45.0% of objective response and a 70.0% of disease control.In patients with metastatic disease, a 7.14% of objective response was obtained (only partial remission), achieving control of the disease in 33.3% of the patients in this stratum. Patients who received 8 or more doses of nimotuzumab reached an 11.5% of objective response, and the disease control increased by 20%.Of the four patients with recurrent disease upon inclusion, 3 achieved a partial response and one stable disease; thus, the control of the disease was achieved in all four.